Chiara Cavallino, Manuela Facchini, Alessia Veia, Sara Bacchni, Andrea Rognoni, Francesco Rametta, Alessandro Lupi and Angelo S. Bongo Pages 14 - 20 ( 7 )
Chronic angina represents a condition that impairs quality of life and is associated with decreased life expectancy in the industrialized countries. Current therapies that reduce angina frequency include old drugs such as nitrates, β -blockers and calcium antagonists. Several new investigational drugs are being tested for the treatment of chronic angina. This review will focus on ranolazine, a drug approved by the US Food and Drug Administration (FDA) in 2006 for patients with chronic angina who continue to be symptomatic despite optimized therapies. The main molecular mechanism underlying ranolazine-mediated beneficial effects has been identified as inhibition of the late Na+ current during the action potential, which potentially improves oxygen consumption, diastolic dysfunction and coronary blood flow. The aim of this review is to update the evidence for ranolazine treatment in chronic angina and discuss its therapeutic perspectives based on the most recent clinical and experimental studies.
Calcium antagonist, coronary artery disease, ranolazine, stable angina, β-blockers, nitrogen.
Catheterization Laboratory, Maggiore della Carità Hospital, Corso Mazzini 18, 28100 Novara, Italy.